Back to top
more

Medpace (MEDP)

(Delayed Data from NSDQ)

$393.91 USD

393.91
110,649

-0.19 (-0.05%)

Updated Jun 14, 2024 03:59 PM ET

After-Market: $393.72 -0.19 (-0.05%) 7:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 249)

Industry: Medical Services

Better trading starts here.

Zacks News

BrainsWay (BWAY) to Advance in DEEP TMS for MDD With New Trial

BrainsWay (BWAY) emphasizes the potential of the accelerated protocol, citing previous data suggesting comparable outcomes with traditional, longer protocols.

Zimmer Biomet (ZBH) Advances in GenAI Technology With RevelAi

Zimmer Biomet (ZBH) and RevelAi Health have joined forces to solve social and clinician problems by commercializing RevelAi's patient care-management platform and care team dashboard for providers.

Thermo Fisher's (TMO) New Launch Supports Full Lab Automation

Thermo Fisher's (TMO) first-of-its-kind innovation for CO2 incubators supports emerging automated cell therapy production processes.

Zimmer Biomet (ZBH) to Broaden Knee Surgery Line With New Alliance

Zimmer Biomet (ZBH) joins forces with Think Surgical for the distribution of customized TMINI - Miniature Robotic System in the U.S. market.

Haemonetics (HAE) Banks on Growing Plasma Arm, Innovation

Haemonetics (HAE) is gaining from the newly completed limited market release of the new Express Plus technology with more than 60,000 real-world collections.

Neogen's (NEOG) MDS Secures New Contract From USDA FSIS

Neogen's (NEOG) MDS gets recognized by the USDA FSIS as the primary method for the detection of Salmonella and Listeria monocytogenes testing for meat, poultry and egg products.

Is Insulet (PODD) Stock an Apt Pick for Your Portfolio Now?

The robust performance of Insulet's (PODD) Omnipod 5 raises investors' optimism. However, concerns remain over the macroeconomic impacts and the company's overdependence on a single platform.

Illumina (ILMN) Advances in NGS With DRAGEN v4.3 Launch

One of the standout features of Illumina's (ILMN) DRAGEN v4.3 is its machine-learning mosaic model.

Abbott's (ABT) AVEIR DR Leadless Pacemaker System Gains CE Mark

Abbott (ABT) receives a CE mark for AVEIR DR, the world's first dual chamber leadless pacemaker system.

Abbott (ABT) Gets FDA Nod for Two Glucose Monitoring Systems

Abbott's (ABT) glucose monitoring systems - Lingo and Libre Rio - based on Freestyle Libre technology, receive FDA clearance.

Myriad Genetics (MYGN) Banks on Innovation Amid Macro Woes

Myriad Genetics (MYGN) continues to enhance its customer targeting, digital marketing and overall operating model to drive commercial leverage in 2024 and beyond.

Charles River (CRL) Partners to Reduce Animal Research Usage

Charles River (CRL) announces the development of non-clinical VCG with Sanofi to reduce the use of animals in research.

Medpace (MEDP) Outperforms Broader Market: What You Need to Know

The latest trading day saw Medpace (MEDP) settling at $405.68, representing a +1.12% change from its previous close.

Align Technology (ALGN) Gains From New Alliances, Global Growth

Align Technology (ALGN) is expanding its sales and marketing by reaching new countries and regions, including new areas within Africa and Latin America.

Capricor (CAPR) Advances in DMD Therapy With Positive Study Data

Capricor (CAPR) anticipates announcing top-line results from the Phase 3 HOPE-3 pivotal trial by the fourth quarter of 2024.

QIAGEN (QGEN) Unveils dPCR Tool, Enhances GeneGlobe Platform

QIAGEN (QGEN) launches the digital PCR Assay Design Tool for QIAcuity and expands the customization capabilities of its GeneGlobe research platform.

Here's Why Omnicell (OMCL) Should be in Your Portfolio Now

A robust Advanced Services portfolio and strategic restructuring initiatives bode well for Omnicell (OMCL).

Nalak Das headshot

5 Growth Stocks to Buy for Steady Returns in June

We have narrowed our search to five growth stocks that have solid upside left for 2024. These stocks are: APP, DDOG, MNDY, MEDP, WING.

Medtronic (MDT) Cardiovascular Business Expands Amid Macro Woes

For Hugo surgical robot, Medtronic (MDT) is scaling manufacturing production, expanding regulatory approvals and ramping up installations to see continued progress internationally.

ICON (ICRL) Gains From Strategic Acquisitions, Innovation

In addition to its focused efforts within the biotech segment, ICON (ICLR) continues to drive forward its leadership in large pharma.

Here's Why Thermo Fisher (TMO) Should be in Your Portfolio

Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).

Nalak Das headshot

U.S. Services PMI Returns to Expansion Path in May: 5 Picks

We have selected five services-oriented stocks that have strong potential for the rest of 2024. These stocks are: MEDP, TXRH, WING, GS, RGA.

Henry Schein (HSIC) Banks on Global Expansion Amid Macro Issues

Within the Dental business, Henry Schein (HSIC) is aiming to deliver customized solutions, leveraging market insights and technological advancements.

IDEXX (IDXX) Expands Test Menu for the Catalyst Platform

IDEXX's (IDXX) new Catalyst Pancreatic Lipase Test is likely to support veterinarians globally in diagnosing pancreatitis.

QIAGEN's (QGEN) New Launch Expands US Syndromic Testing Menu

QIAGEN's (QGEN) new QIAstat-Dx Gastrointestinal Panel 2 offers fast and accurate identification of up to 16 common gastrointestinal pathogens.